title: [Pharmacogenomic data for personalized medicines].
abstract: FDA issued guidance for industry regarding pharmarcogenomic data submission this year. Polymorphic cytochrome P450 2D6 and thiopurine S-methyltransferase in patients are now considered biomarkers for drugs which are predominantly metabolized by these enzymes. This article reviews current efforts to treat pharmacogenomic data for new drug development and personalized medicines.
authors.affiliation: Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yamazaki
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000378:metabolism*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D014453:Glucuronosyltransferase / Q000235:genetics; D019983:Guideline Adherence; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D010597:Pharmacogenetics
chemical_list: D000970:Antineoplastic Agents; D019389:Cytochrome P-450 CYP2D6; D014453:Glucuronosyltransferase